[1] |
LEE J Y, BAEK J H, HA E J, et al. 2020 imaging guidelines for thyroid nodules and differentiated thyroid cancer: Korean society of thyroid radiology[J]. Korean J Radiol, 2021, 22(5): 840-860.
doi: 10.3348/kjr.2020.0578
|
[2] |
HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
doi: 10.1089/thy.2015.0020
|
[3] |
TAN L C, HUANG N S, YU P C, et al. Different clinicopathologic features predispose to different patterns of distant metastasis with heterogeneous short-term prognosis in patients with differentiated thyroid cancer[J]. Clin Endocrinol (Oxf), 2022, 96(3): 402-412.
doi: 10.1111/cen.14602
|
[4] |
GRØNLUND M P, JENSEN J S, HAHN C H, et al. Risk factors for recurrence of follicular thyroid cancer: a systematic review[J]. Thyroid, 2021, 31(10): 1523-1530.
doi: 10.1089/thy.2020.0921
pmid: 34102860
|
[5] |
ILHAN H, MUSTAFA M, BARTENSTEIN P, et al. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study[J]. Nuklearmedizin, 2016, 55(6): 221-227.
pmid: 27588323
|
[6] |
CHUDGAR A V, SHAH J C. Pictorial review of false-positive results on radioiodine scintigrams of patients with differentiated thyroid cancer[J]. Radiographics, 2017, 37(1): 298-315.
doi: 10.1148/rg.2017160074
pmid: 28076008
|
[7] |
SCHMIDT D, LINKE R, UDER M, et al. Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation[J]. Eur J Nucl Med Mol Imaging, 2010, 37(4): 699-705.
doi: 10.1007/s00259-009-1299-2
|
[8] |
KIM H, KIM Y N, KIM H I, et al. Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer[J]. Sci Rep, 2017, 7(1): 16955.
doi: 10.1038/s41598-017-17176-6
pmid: 29209067
|
[9] |
LI S, REN C T, GONG Y, et al. The role of thyroglobulin in preoperative and postoperative evaluation of patients with differentiated thyroid cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 872527.
doi: 10.3389/fendo.2022.872527
|
[10] |
郭彦君, 王叙馥, 王国强, 等. 分化型甲状腺癌术后131I清灶疗效及影响因素分析[J]. 中华核医学与分子影像杂志, 2017, 37(11): 705-709.
|
[11] |
GUO Y J, WANG X F, WANG G Q, et al. Efficacy and influential factors of post-resection 131I therapy on metastases from differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imaging, 2017, 37(11): 705-709.
|
[12] |
REN L, ZHANG C L, SHEN Y, et al. The value of stimulated thyroglobulin before the first radioactive iodine treatment in metastasis for differentiated thyroid carcinoma[J]. Clin Lab, 2021, 67(6).
|
[13] |
HAN Y, HOU L, ZHAO B W, et al. Risk factors for neck nodal metastasis in papillary thyroid cancer with BRAF V600E mutation[J]. Front Endocrinol (Lausanne), 2022, 13: 884428.
doi: 10.3389/fendo.2022.884428
|
[14] |
WEI X J, WANG X D, XIONG J, et al. Risk and prognostic factors for BRAF V600E mutations in papillary thyroid carcinoma[J]. Biomed Res Int, 2022, 2022: 9959649.
|
[15] |
RASHID F A, MUNKHDELGER J, FUKUOKA J, et al. Prevalence of BRAF V600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review[J]. Gland Surg, 2020, 9(5): 1878-1900.
doi: 10.21037/gs-20-430
|
[16] |
SCHOULTZ E, JOHANSSON E, MOCCIA C, et al. Tissue architecture delineates field cancerization in BRAF V600E-induced tumor development[J]. Dis Model Mech, 2022, 15(2): dmm048887.
doi: 10.1242/dmm.048887
|
[17] |
CAZARIN J, DUPUY C, PIRES DE CARVALHO D. Redox homeostasis in thyroid cancer: implications in Na + /I-symporter (NIS) regulation[J]. Int J Mol Sci, 2022, 23(11): 6129.
doi: 10.3390/ijms23116129
|
[18] |
DI GIUSTO P, MARTÍN M, et al. FUNES CHABÁN M, Transcription factor CREB3L1 regulates the expression of the sodium/iodide symporter (NIS) in rat thyroid follicular cells[J]. Cells, 2022, 11(8): 1314.
doi: 10.3390/cells11081314
|
[19] |
KIM K J, KIM S G, TAN J, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma[J]. Eur J Cancer, 2020, 124: 161-169.
doi: S0959-8049(19)30780-4
pmid: 31790974
|
[20] |
WANG T T, SHI J Y, LI L C, et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma[J]. Front Immunol, 2022, 13: 840811.
doi: 10.3389/fimmu.2022.840811
|
[21] |
卢承慧, 李娇, 刘新峰, 等. 首次131I治疗后淋巴结显影伴治疗前刺激性Tg阴性的分化型甲状腺癌的治疗反应及影响因素分析[J]. 中华核医学与分子影像杂志, 2020, 40(1): 21-26.
|
[22] |
LU C H, LI J, LIU X F, et al. Treatment response of differentiated thyroid carcinoma with negative preablative stimulated thyroglobulin and iodine-positive lymph node after the first radioablation and influence factors analysis[J]. Chin J Nucl Med Mol Imaging, 2020, 40(1): 21-26.
|